U.S. Supreme Court to Hear Case on Patent Exhaustion

Dec 8, 2016

Reading Time : 2 min

The patent exhaustion doctrine, or “first sale doctrine,” requires that the initial authorized sale of a patented item terminate all patent rights to that item. The Court of Appeals for the Federal Circuit, however, has recognized two exceptions to this doctrine. First, in Mallinckrodt, Inc. v. Medipart, Inc., the Federal Circuit held that a patentee may transfer title to the patented article and specify a post-sale reuse or resale restriction on the article that may be enforced by patent laws. See 976 F.2d 700.  Second, in Jazz Photo Corp. v. International Trade Commission, the Federal Circuit held that a patentee’s U.S. patent rights are not exhausted when it sells the patented article outside the United States. See 264 F. 3d 1094.

Lexmark is a printer manufacturer that makes and sells patented toner cartridges for its printers. Impression Products is a remanufacturer of toner cartridges. In 2010, Lexmark brought suit against Impression Products and other remanufacturers for patent infringement. See Lexmark Int’l, Inc. v. Impression Prods., 816 F.3d 721, 728-729 (Fed. Cir. 2016).  Impression Products moved to dismiss Lexmark’s claims on the grounds that Lexmark exhausted its U.S. patent rights in the cartridges in two manners. First, Impression Products argued that Lexmark’s single-use/no-resale requirement was an invalid post-sale restriction under the Court’s decision in Quanta, 553 U.S. at 637. Id. at 731. Second, Impression Products argued that Lexmark exhausted its patent rights as to cartridges first sold abroad under the Court’s copyright exhaustion analysis in Kirtsaeng, 133 S. Ct. 1351 (2013). Id. at 731-32.

The district court for the Southern District of Ohio held that Lexmark did not exhaust its U.S. patent rights in toner cartridges that Lexmark initially sold abroad. Lexmark, 816 F.3d at 730. The district court further held, however, that the patent exhaustion doctrine barred Lexmark’s patent infringement regarding toner cartridges that were first sold by Lexmark in the United States, concluding that post-sale use restrictions did not preclude patent exhaustion after an authorized sale under Quanta. Id.

After subsequent appeals by both parties, in February 2016, the Federal Circuit en banc issued a 10-2 decision reaffirming that foreign sales do not exhaust patent rights and holding that post-sale use restrictions preclude patent exhaustion after an authorized sale.

Impression Products petitioned for a writ of certiorari regarding the scope of patent exhaustion with respect to foreign sales and post-sale use restrictions. The Court will hear both issues. This is the fourth patent case the Court has taken this term.

Impression Products, Inc. v. Lexmark International, Inc., 15-1189

Share This Insight

Previous Entries

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

IP Newsflash

April 23, 2025

The Federal Circuit recently refused to apply collateral estoppel to claims of a patent asserted in district court litigation based on a Patent Trial and Appeal Board (PTAB) decision finding similar claims from the same patent unpatentable because the PTAB applied a lower burden of proof than what is required to invalidate claims in district court.

...

Read More

IP Newsflash

April 7, 2025

The Central District of California denied a defendant’s motion to dismiss or transfer plaintiff’s first-filed declaratory judgment action based on defendant’s later-filed patent infringement suit in Wisconsin.  Though suit was seemingly imminent when defendant advised plaintiff it might be infringing defendant’s patents, plaintiff responded by requesting a licensing agreement in lieu of litigation. The court found that plaintiff’s action was not anticipatory forum-shopping litigation because plaintiff only filed suit after defendant neglected to respond to its licensing offer.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.